Chinook Therapeutics, Inc. (KDNY)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY). Investors who purchased Chinook securities are encouraged to obtain additional information and assist the investigation.                                         

The investigation concerns whether Chinook has violated federal securities laws.

On May 16, 2023, Muddy Waters Research issued a report on Chinook, alleging that atrasentan, the Company’s lead product candidate, “has been shown to be harmful to patients’ cardiovascular health”, and that “AbbVie and Chinook seem to have systemically manipulated research findings and presentation on atrasentan to obscure these trial results.”  Following this news, Chinook’s stock price fell $1.05 per share, or 4.49%, to close at $22.35 on May 16, 2023.

If you are aware of any facts relating to this investigation or purchased Chinook shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.